Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)

Multiple Myeloma Clinical Trial

Official title:

Efficacy and Safety Study of Anti-FcRL5 CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06196255
• Other study ID #: XYFY2023-KL216-01
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: December 25, 2023
• Est. completion date: January 1, 2028

Study information

• Verified date: December 2023
• Source: Xuzhou Medical University
• Contact: Kailin Xu, MD.,PD.
• Phone: 15162166166
• Email: lihmd[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Description:

This open label, single-arm, Phase 2 study aims to evaluate the efficacy and safety of Anti-FcRL5 CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture. Anti-FcRL5 chimeric antigen receptor (CAR) modified T cells. Prior to Anti-FcRL5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable agent MTD and rp2d were confirmed. To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: January 1, 2028
• Est. primary completion date: January 1, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

The set subject inclusion criteria include multiple documents of multiple myeloma, no effective treatment options (e. g. autologous or allogeneic stem cell transplantation) and

limited outcome (<2 years) with existing therapies, as follows:

1. Age is 18~70 years old;

2. Expected survival period of>12 weeks;

3. Multiple myeloma was diagnosed by physical examination, pathological examination, laboratory examination and imaging;

4. Patients with refractory multiple myeloma;

5. Patients with multiple myeloma recurrence;

6. ALT and AST <3 times normal; bilirubin <2.0mg / dl;

7. Quality of survival score (KPS)> 50%;

8. The patient has no serious heart, liver, kidney and other diseases;

9. Recurrence or no disease remission after hematopoietic stem cell transplantation or cellular immunotherapy;

10. Is not suitable for stem cell transplantation conditions or to abandon transplantation due to conditional restrictions;

11. Blood can be obtained intravenously, without other contraindications to leukapheresis;

12. Understand and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Women who are pregnant or breastfeeding, or who have a pregnancy plan within six months;

2. Infectious diseases (such as HIV, active tuberculosis, etc.);

3. Active hepatitis B or hepatitis C infection;

4. Feasibility assessment screening demonstrated <10% transfection of targeted lymphocytes or underamplification under CD3 / CD28 costimulation (<5-fold);

5. Abnormal vital signs, and unable to cooperate with the examination;

6. Have mental or mental illness who cannot cooperate with the treatment and efficacy evaluation;

7. Highly allergic constitution or have a history of severe allergies, especially allergic to IL-2;

8. Subjects with a systemic infection or a severe local infection requiring anti-infective treatment;

9. Subjects with severe autoimmune disease;

10. The doctor believes there were other reasons for inclusion

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• anti-FcRL5 CAR-T
anti-FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.

Locations

Country	Name	City	State
China	The affiliated hospital of Xuzhou Medical University	Xuzhou	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse events	Adverse events assessed according to NCI-CTCAE v5.0	Baseline up to 28 days after CAR-T cells infusion
Secondary	overall response rate (ORR)	Assessment of ORR at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24
Secondary	complete response (CR)	Assessment of CR at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24
Secondary	Overall survival (OS)	Assessment of OS at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24
Secondary	Event-free survival (EFS)	Assessment of EFS at Month 6, 12, 18 and 24	Month 6, 12, 18 and 24